Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.

Abstract

Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed. Germline mutations in 12 established BC predisposition genes (including <i>BRCA1</i> and <i>BRCA2</i>) were detected in 271 (10.4%) patients. A mutation in <i>BRCA1</i> or <i>BRCA2</i> was seen in 129 patients (5.0%). <i>BRCA1</i> mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% <i>v</i> 6.6%, <i>P</i> < .01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC. Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in <i>BRCA1/2</i> and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.